<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="148135">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02094287</url>
  </required_header>
  <id_info>
    <org_study_id>PlacItch</org_study_id>
    <secondary_id>2008-008474-31</secondary_id>
    <nct_id>NCT02094287</nct_id>
  </id_info>
  <brief_title>Placebo Effect in the Treatment of Atopic Dermatitis</brief_title>
  <official_title>Placebo Effect in Atopic Dermatitis - Increase the Pharmacological Effect of Itching Caused by Classical Conditioning and Expectancy Processes: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Margitta Worm</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is initiated in the indication of atopic dermatitis to study the impact of placebo
      in the treatment of pruritus. Classical conditioning and anticipation maintain the effect of
      placebo.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)</study_design>
  <primary_outcome>
    <measure>Comparison of pruritus intensity on a 10-point-rating scale between the groups</measure>
    <time_frame>assessed over a time frame of 2 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>The pruritus intensity is assessed at different time points during a time frame of 2 days. The results are compared between the groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of the severity of atopic dermatitis (SCORAD) and comparison between the groups</measure>
    <time_frame>assessed over a time frame of 2 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change of SCORAD is assessed on day 1 and day 2.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>verum, instruction, conditioning</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group received dimetindene and instruction.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>verum, instruction, no conditioning</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group received dimetindene and instruction.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo, instruction, no conditioning</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group does not receive dimetindene, but instruction.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>verum, no instruction, no conditioning</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group received dimetindene but no instruction.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dimetindene</intervention_name>
    <arm_group_label>verum, instruction, conditioning</arm_group_label>
    <arm_group_label>verum, instruction, no conditioning</arm_group_label>
    <arm_group_label>verum, no instruction, no conditioning</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>instruction</intervention_name>
    <arm_group_label>verum, instruction, conditioning</arm_group_label>
    <arm_group_label>verum, instruction, no conditioning</arm_group_label>
    <arm_group_label>placebo, instruction, no conditioning</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>conditioning</intervention_name>
    <arm_group_label>verum, instruction, conditioning</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  SCORAD-Score &lt; 50 points

          -  basic pruritus &gt; and equal 3 points

        Exclusion Criteria:

          -  intake of antihistamines

          -  pregnancy and lactation
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margitta Worm, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sabine Dölle, PhD</last_name>
    <phone>+49-30-450518</phone>
    <phone_ext>367</phone_ext>
    <email>sabine.doelle@charite.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Charité - University Medicine Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine Dölle, PhD</last_name>
      <phone>+49-30-450518</phone>
      <phone_ext>367</phone_ext>
      <email>sabine.doelle@charite.de</email>
    </contact>
    <investigator>
      <last_name>Worm Margitta, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 20, 2014</lastchanged_date>
  <firstreceived_date>March 17, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Margitta Worm</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dimethindene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
